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 “What is new” 
Key findings: 
1. Few studies have assessed core outcome set (COS) uptake (17/337 (5%) COS assessed) 
2. There is wide variation in COS uptake across different health areas 
What this adds to what is known: 
3. This review will serve as a benchmark for comparing uptake going forward   
What is the implication, what should change now: 
4. Barriers and facilitators to COS uptake should be explored 
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Objective 
The aim of our review was to bring together studies that had assessed the uptake of core outcome 
sets (COS) to explore the level of uptake across different COS and areas of health. 
Study Design and Setting 
We examined the citations of 337 COS reports to identify studies that had assessed the uptake of a 
particular COS in randomised controlled trials (RCTs) or systematic reviews (SRs).   
Results 
We identified 24 studies that had assessed uptake in RCTs and two studies that has assessed uptake 
in SRs.  The studies covered a total of 17/337 (5%) COS.  Uptake rates reported for RCTs varied from 
0% of RCTs (gout) to 82% RCTs (rheumatoid arthritis) measuring the full COS.  Studies that assessed 
uptake of individual core outcomes showed wide variation in uptake between the outcomes.  
Suggested barriers to uptake included lack of validated measures, lack of patient and other key 
stakeholder involvement in COS development and lack of awareness of the COS. 
Conclusions 
Few studies have been undertaken to assess the uptake of COS in RCTs and SRs.  Further studies are 
needed to assess whether COS have been implemented across a wider range of disease categories 
and to explore the barriers and facilitators to COS uptake. 
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1. Introduction 
In 2014 Gargon et al., under the auspices of the COMET (Core Outcome Measures for Effectiveness 
Trials) Initiative, published a systematic review bringing together studies that had made 
recommendations about which outcomes to measure in clinical trials of specific health conditions(1).  
Such recommendations, known as Core Outcome Sets (COS), are defined by the COMET Initiative as 
“an agreed standardised set of outcomes that should be measured and reported, as a minimum, in 
all clinical trials in specific areas of health or health care”.  Gargon’s review identified 250 
publications relating to 198 COS that had been developed up to August 2013.  Following the initial 
review, updates have been published annually(2-6) with the latest bringing the number of COS to 
364, described in 403 publications, up to the end of 2018.  As of March 2020, a further 267 COS in 
development were registered in the database maintained by the COMET Initiative (www.comet-
initiative.org/Studies).  
 
The development of COS tackles problems with outcomes in trials, including lack of standardisation, 
which hampers evidence synthesis(7), outcome reporting bias(8), and relevance of the outcomes (9).  
Through the involvement of key stakeholders and the use of consensus methods to agree the set of 
core outcomes, COS can provide the consistency and relevance needed to address the problems 
with outcomes in trials and other research.  However, patients, healthcare professionals and all 
Jo
urn
al 
Pr
e-p
r o
f
other end users of trial results will only benefit from COS if researchers choosing outcomes for trials 
include them in their studies.  In addition, there is a danger that the continuous development of 
COS, without uptake, will itself result in research waste, contrary to the rationale for COS.   
 
It is therefore important that COS developers consider what steps they can take to increase uptake 
of their COS and monitor its use to establish whether uptake is being achieved.  Assessing the uptake 
of COS in clinical trials, or systematic reviews of trials, offers COS developers the opportunity to 
revisit their strategies for promoting uptake where this is found to be low.  An assessment of uptake 
can also allow developers to review the relevance of their COS.  For example, if outcomes in the COS 
are not being used, or trials are consistently measuring an outcome that does not appear in the COS, 
an update may be suggested. 
 
As the number of COS continues to grow, we did this review to identify studies that have evaluated 
the uptake of a COS, explore the level of uptake across different areas of health, and review the 
methods used to assess uptake. 
 
2. Methods 
The protocol is available at http://www.comet-initiative.org/Studies/Details/1575 
2.1 Identification of relevant studies 
Citation analysis 
Studies were identified by reviewing the citations received by articles reporting a COS published 
between 1981 and July 2016.  The rationale for this method was that a study assessing uptake of a 
COS should cite the publication reporting that COS.  We set this timeframe because the first COS 
article that we are aware of was published in 1981 and we started accessing citation reports in July 
2018.  A cut-off date of July 2016 for the publication of the COS was likely to allow sufficient time for 
the COS to be cited in an uptake study.  We included 337 COS publications identified from the 
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COMET Initiative’s systematic reviews that had been published at the time of data collection(1-5) 
(Supplementary File A for included COS publications).  We accessed the citation reports for each COS 
publication using Scopus, which has been found to include more articles for citation analysis than 
Web of Science and is more up to date than Google Scholar(10).  
 
Scopus alerts 
To ensure that this review remained current, an alert was set in Scopus to capture studies of COS 
uptake published after July 2018 that would not appear in our citation search. 
 
2.2 Inclusion and exclusion criteria 
Studies were included if they had assessed the uptake of the outcomes recommended by the COS, 
either individually or as a full set, by randomised controlled trials (RCTs) or systematic reviews (SRs).  
If studies had assessed uptake in additional types of study, e.g. observational studies, we only 
included data for the RCTs and SRs in our results.  We included studies that had reported data that 
allowed the COS uptake rate to be calculated, even if COS uptake was not the main purpose of the 
study.  Studies were ineligible if they had assessed uptake of outcome measures without an 
assessment of the recommended outcome domains.  Studies were excluded if they had not assessed 
uptake of all of the outcomes in the COS, e.g. if they had only assessed uptake of the patient 
reported outcomes recommended by the COS, in order to ascertain the level of compliance with the 
full recommendations of the COS and make comparisons across health areas. 
 
2.3 Selecting studies for inclusion 
The references and abstracts of all publications that had cited the 337 COS articles were identified 
using Scopus and exported into Microsoft Excel.  If a reference appeared more than once in the Excel 
file, because the publication had cited more than one COS article and therefore appeared in more 
than one COS article’s citation report, we removed the duplicate references.  We searched the titles 
Jo
urn
al 
Pr
-pr
oo
f
of each citing publication using keywords relating to COS and uptake to identify possible studies of 
COS uptake (Supplementary File B for keywords).  The resulting titles were assessed, followed by a 
review of the abstract for those judged to be possible studies of COS uptake.  Full texts were 
examined for those where it was judged from the abstract that the publication may be reporting an 
assessment of the uptake of a COS or where an abstract was not available.  The references in each of 
the eligible studies were checked for further studies of COS uptake. 
 
2.4 Checking for correct exclusion 
To confirm the assessment of titles by the first reviewer (KH), a second reviewer (PW) independently 
assessed 50 titles.  As complete agreement was reached on inclusion and exclusion of articles at this 
stage, KH completed the rest of the title assessments.  PW reviewed 20 abstracts and agreed with 
KH’s assessment, who then completed this stage.  The full texts of 10 articles excluded at title stage 
and 20 articles excluded at abstract stage were checked by KH for correct exclusion.  
 
2.5 Data extraction 
For each eligible study, the following data were extracted and recorded in a data collection form: 
disease category, disease name, scope of the uptake study, period covered by the assessment, 
number of RCTs/SRs assessed, % RCTs/SRs that measured the full COS and/or % RCTs/SRs that 
measured each individual outcome in the COS, the method used to assess uptake and suggested 
barriers and facilitators for uptake.  The scope was defined in terms of the population with the 
health condition and/or intervention type for which RCTs/SRs were identified and assessed for COS 
uptake. 
 
2.6 Data analysis 
The results of the review are presented descriptively.  We did not carry out any statistical analyses to 
synthesize the data.   
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 3. Results 
3.1 Studies identified 
The 337 COS publications received a combined total of 55,693 citations with 51,122 remaining once 
duplicates had been removed.  The titles of 10,085 of the citing articles contained at least one of the 
keywords.  Following the screening of titles and abstracts, 345 full texts were examined, including 
articles that had no abstract, leading to the identification of 19 studies of COS uptake (Figure 1).  A 
further seven studies were identified via Scopus alerts.  We did not identify any additional studies 
after checking the references of the included studies.  Four studies were excluded because they did 
not assess uptake of all outcomes that were recommended by the COS.  One of these studies 
assessed uptake of a resource use domain only, while another assessed only uptake of the patient 
reported outcomes recommended by the COS.  A third study focused on measurement instruments 
and included an assessment of uptake of some, but not all, COS outcomes and the final study 
assessed uptake of a selection of outcomes from a COS that is made up of 48 recommendations.  
Supplementary File C shows the references of all included studies and the COS they assessed.  The 
26 studies assessed uptake for a total of 17 COS, with five COS being assessed by more than one 
study.  Thus, we found that 17/337 (5%) COS had been assessed for uptake.  
 
3.2 Description of studies 
Twenty-four studies assessed uptake in RCTs and two studies assessed uptake in SRs (Table 1).  The 
COS assessed were published between 1982 and 2014 and recommended between one and 19 
outcomes, with the majority (n = 12; 71%) comprising of seven outcomes or fewer.  The studies 
assessed between eight and 382 RCTs and the two assessing SRs included 48 and 90.  The 26 studies 
covered five of 31 disease categories where COS have been developed (Figure 2).  Just over half of 
the studies (n=14) assessed uptake of a rheumatology COS.  The other studies assessed uptake of 
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COS developed in the categories of anaesthesia and pain control (n=7), orthopaedics and trauma 
(n=3), neurology (n=1) and skin (n=1). 
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Table 1: Studies assessing uptake of COS in RCTs and SRs 
COS disease 
category 
COS disease name Year COS 
published 
No. outcomes 
in COS 
Scope of uptake study Period assessed 
for uptake of COS 
No. RCTs 
assessed 
% RCTs measuring each 
COS outcome 
% RCTs measuring full COS 
Rheumatology Psoriatic arthritis 2007 6 Psoriatic arthritis
A4
 2006 – 2010 17
 
77, 71, 59, 53, 47, 47 24 
Psoriatic arthritis
A13
 2010 - 2015 22
 
100, 95, 91, 86, 82, 77 59 
Knee, hip, and hand 
osteoarthritis 
1997 5*
1 
Trapeziometacarpal 
osteoarthritis
A5
 
          - 2010 316*
2 
96, 94, 67, 59, 4 - 
  3 + 1 (> 1 year) Total knee anthroplasty
A16
            - 2014 30
 
93, 27, 10*
3
  7 
   Hip or knee 
osteoarthritis
A23
 
1997 - 2017 382 95, 86, 75, 48 45 
   Osteoarthritis
A25
 2012 – 2017 334 97, 84, 17, 30 14 
Rheumatoid 
arthritis 
1982*
4 
 
1989 
10 
 
7 
DMARD therapy for 
rheumatoid arthritis
A1
 
1986 – 1990 32 100, 91, 91, 91, 91, 73, 73, 
64, 55, 55 
100, 91, 91, 91, 73, 55, 27 
- 
 
 
 1994 7 + 1 (> 1 year) Rheumatoid arthritis
A2 
2005 – 2007 50*
5
 - 82 
   Rheumatoid arthritis
A6
            - 2009 350
 
 60-70*
6 
Rheumatoid arthritis
A17
 2002 – 2016 143
 
- 81 
Rheumatoid arthritis
A22
 2009 - 2019 197
 
- Just over 80 
Ankylosing 
spondylitis 
1997 6 (SMARD) 
9 (DC-ART) 
Ankylosing 
spondylitis/axial 
spondyloarthritis
A7
 
           - 2013 99
 
92, 84, 77, 51, 46, 44   
97, 97, 92, 84, 82, 79, 68, 
63, 16 
20 
Acute and chronic 2009 5 (acute) Acute gout
A8
            - 2011 77*
7 
99, 57, 51, 32, 5 - 
gout  2005 5 (acute) 
9 (chronic) 
Acute and chronic gout
A11
            - 2013 38*
8 
30*
8 
87, 79, 71, 29, 8,  
80, 73, 70, 10, 7, 3, 0, 0, 0 
5 
0 
Anaesthesia & 
pain control 
Chronic pain 2008 19 Cognitive and/or 
behavioural treatment
A3
 
           - 2010 60 94, 83, 12 domains >40, 5 
domains 0 
- 
  2003 6 Acceptance and 
Commitment Therapy
A9
 
1999 - 2014 10 90, 90, 80, 70, 10, 10 - 
    Burning mouth 
syndrome
A21
 
1994 – 2017 36 100, 97, 78, 33, 28, 22 11 
  2003 
2008 
(update) 
6 
3 
Opioids for chronic non-
cancer pain
A10
 
           - 2012 156 99, 94, 76, 46, 43, 31, 28, 
19, 7 
- 
 Pediatric acute and 2008 6 Postoperative pain            - 2017 337 93, 83, 21, 16, 15, 15 - 
Jo
urn
l P
re-
pro
of
chronic pain management
A18
 
Orthopaedics 
& Trauma 
Fall injury 2005 5 Fall prevention in older 
people
A14
 
2005 – 2015 34 94, 47, 24, 24, 21 3 
 Spinal cord injury 2007 1 Anticholinergic therapy for 
neurogenic bladder in 
SCI
A15
 
1946 – 2015 14 3 3 
 Hip fracture 2014 5 Hip fracture
A24
 1997 – 2018 311 47, 46, 41, 37, 29 12 
Neurology Peripheral 
neuropathy 
2006 3 Multifocal motor 
neuropathy
A12
 
1995 – 2014 8 100, 100, 13 13 
Skin Eczema 2011 4*
9 
Atopic eczema 
treatments
A26
 
2005 – 2018 177 - 25%*
10 
33%*
11 
         
      No. SRs 
assessed 
% SRs measuring each 
COS outcome 
% SRs measuring full COS 
Anaesthesia & 
pain control 
Chronic pain 2003 6 Neuropathic pain 
conditions
A19
 
- 2015 90 94, 84, 53, 50, 49, 29 10 
 Pediatric acute and 
chronic pain 
2008 6 Postoperative pain
A20
 - 2017 48 88, 75, 29, 21, 19, 15 - 
*
1 
assessed all 4 inner core domains plus 1 middle core domain 
*
2 
includes RCTs and observational studies 
*
3 
Uptake of 1 outcome not reported individually but included in full uptake assessment 
*
4 
Study included 2 COS 
*
5 
Excluded trials from assessment if they did not report at least 1 patient reported outcome (PRO) 
*
6 
in 2009 
*
7 
Excluded trials from assessment if they did not report at least 1 core outcome 
*
8
 includes quasi-RCTs (3 acute, 2 chronic) 
*
9
 3 domains assessed as 1 domain not defined at time of review 
*
10 
Average from 2005 – 2018 
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*
11
 in 2018 
A1-A26
 corresponds to uptake study listed in Supplementary File C 
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3.3 Methods used to assess uptake 
Seventeen (65%) studies identified the RCTs or SRs that they would assess by carrying out a 
systematic literature review(11-27).  They extracted data about the outcomes included from the RCT 
reports and SRs.  Two (8%) studies searched SRs to identify RCTs(28, 29) and one (4%) study included 
RCTs identified from one systematic review(30).  Five (19%) studies identified RCTs by searching a 
clinical trials registry(31-35).  One (4%) study identified RCTs through the citations received by the 
COS that they assessed and estimated the total number of RCTs as a denominator(36).  Twenty-one 
studies (81%) reviewed outcomes measured by their selected RCTs or SRs before the COS was 
published, or from the year of publication, as well as after.  For those that only assessed the 
outcomes measured after publication of the COS, the COS had been published for at least three 
years before the start of the uptake assessment period. 
 
3.4 Uptake of the COS in full by RCTs and SRs 
Seventeen studies reported the proportion of RCTs that measured the full set of outcomes 
recommended by a COS and one study reported this for SRs (Table 1).  For four of the eight 
remaining studies, uptake assessment was not their main aim and the other four studies did not 
indicate why they had not assessed uptake of the complete COS.  For RCTs, the lowest rate of uptake 
reported was 0% (gout) and the highest 82% (rheumatoid arthritis), and 10% uptake was found by 
the study assessing SRs.   Eleven of the COS had at least one study assessing uptake of the COS in full 
and for eight of these (73%), at least one such study reported that a maximum of 20% or less of the 
RCTs or SRs assessed had measured the full COS.  The assessed COS had recommended between one 
and 19 outcomes (Table 1).  The COS with the least number of outcomes (n=1) had an uptake rate of 
3% of RCTs measuring the full COS.  No RCT measured the full COS with the highest number of 
outcomes (n=19), implicit from the fact that some of the outcomes were not measured in any RCT.  
The COS with the highest level of uptake recommended seven outcomes (plus one extra outcome 
for RCTs lasting more than one year) (Figure 3).
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3.5 Uptake of individual outcomes in the COS by RCTs and SRs 
Nineteen studies of RCTs reported the uptake of each outcome recommended by the COS, as did 
both studies of SRs (Table 1).  The results showed wide variation in the uptake rate for the individual 
outcome in each COS.  For example, one of those studies, assessing uptake of a COS for chronic pain, 
found that one outcome (pain) was included in 99% of trials while another (interpersonal 
functioning) was included in only 7%(21).  The authors of five studies suggested that a review of the 
COS may be needed to address this and one study planned to use its findings to update the COS, 
which was for psoriatic arthritis (PsA)(12).  Six outcomes out of a total of 133 across all studies of 
uptake in RCTs were reported by 100% of RCTs and two of the six were from the same COS.  None of 
the RCTs in one study for chronic gout measured three of the outcomes in the COS (which had nine 
COS outcomes in total) and none of the RCTs in a study for chronic pain measured 5 of the outcomes 
in the COS (19 outcomes in total). 
 
3.6 Suggested barriers to uptake of COS 
One of the studies investigated reasons for lack of uptake with the trialists directly(28) and reported 
that the majority of trialists not measuring the full COS were not aware of it when designing their 
trial.  A further 15 studies suggested potential barriers that may have resulted in low uptake of the 
COS (Table 2).  The absence of validated measures, or no consensus on which instruments should be 
used to assess the domains, was noted in two studies(11, 29).  Six studies referred to limited patient 
or other key stakeholder involvement in the development of the COS as a potential barrier to 
uptake.  Other barriers suggested were poor understanding of COS amongst trialists, lack of clarity, 
patient burden, cost and lack of standardised recommendations across regulatory agencies. 
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Table 2: Suggested barriers to uptake of COS 
Reason for low uptake Number (%) of 
studies 
mentioning this 
reason 
Example 
Lack of validated 
measures/no consensus 
on measures 
8 (31) “There may also be applicability issues 
due to a lack of consensus regarding 
instruments to assess each domain.”
A4
 
Lack of awareness 5 (19) “This appears to be associated with the 
lack of awareness of the researchers 
regarding the existence of this 
standardized set of outcomes.”
A21
 
Lack of patient 
involvement 
4 (15) “Further work is needed to obtain a 
better insight into what is relevant to the 
patient…”
A2
 
Limited stakeholder 
involvement 
2 (8) “…the limited stakeholder involvement in 
the development of the hip fracture core 
outcome set may undermine its fitness for 
purpose.”
A24
 
Poor understanding of 
COS 
2 (8) “…authors may not understand the 
purpose of core sets…”
A7
 
Lack of clarity 1 (4) “Precise definition of PsA Core Domains is 
necessary…”
A13
 
Patient burden 1 (4) “Patients, for instance, may experience 
the requirement to complete these 
measures as an onerous burden…”
A10
 
Cost 1 (4) “Previous research suggests some trialists 
do not measure damage as it is costly to 
measure and requires further expenditure 
to obtain valid readings of radiographs”
A22
 
Lack of standardised 
recommendations 
across regulatory 
agencies 
1 (4) “Some of this discordance may account 
for lack of uptake, and therefore future 
work may be undertaken to standardize 
recommendations across regulatory 
authorities.” 
A23
 
 
A
 corresponds to uptake study listed in Supplementary File C 
 
 
 
 
 
4. Discussion 
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There are currently few studies of COS uptake.  The studies we identified covered five disease 
categories with just over half of the uptake assessments being carried out for COS that had been 
developed for rheumatic diseases.  Rheumatology has the second highest number of published COS 
and another two of the five disease categories with the most published COS (neurology and 
orthopaedics and trauma) had at least one study assessing uptake of COS in its area(5).  We did not 
find any studies assessing the uptake of COS for cancer, which has the highest number of COS of all 
disease categories(5).  For the remaining 25 disease categories that have at least one published COS, 
we did not find an assessment of uptake of any COS in these categories.   
 
The studies included in our review used various methods to assess uptake of COS.  Most examined 
reports of RCTs that they had identified by reviewing the literature or searching systematic reviews.  
Not only are these lengthy processes, the information about the outcomes measured is not current 
as the outcomes would likely have been chosen some years before the trial reports were published.  
One study identified RCTs from the citations received by the COS publication.  However, a previous 
study into citation analysis as a method for COS uptake assessment found that not all RCTs using a 
COS cite the COS publication(37).  A third method used, which removes the need to examine the 
report of the RCT and provides up to date information about the outcomes being measured, 
involved extracting information about outcomes from a trial registry.  One of the uptake studies 
assessing the RA COS(31) tested this approach using ClinicalTrials.gov.  The authors concluded that 
the uptake rate obtained by using information listed in the registry alone (77%) was an acceptable 
estimate of the uptake rate found by identifying the RCTs on the registry and examining the results 
in the registry or report of the RCT (81%).  This approach provides an efficient method to assess 
uptake, which may encourage further assessments to be carried out. 
 
The studies that found low uptake of COS observed a number of barriers that might have hampered 
their use:  
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(i) To address a lack of patient and other key stakeholder involvement, and the issue of relevance of 
outcomes in existing COS, it may be prudent to consider an update to the COS.  The importance of 
patient involvement in COS development is being recognised by developers of new COS, with 94% of 
ongoing COS developers who responded to a 2017 survey stating that they had included patient 
participants(38).  Whilst patient involvement may not in itself affect COS uptake, the relevance of 
COS will be improved with input from patient representation.  Involving a range of key stakeholders 
when developing COS in addition to patients, for example, healthcare professionals, researchers and 
those who might use the COS, may further improve the relevance of the outcomes selected for 
inclusion.   
 
(ii) To tackle uncertainty around instruments and measures COS developers should focus on 
determining how to measure the outcomes in the COS once consensus has been reached on what to 
measure.  The COMET and COSMIN (COnsensus-based Standards for the selection of health 
Measurement Instruments) Initiatives have developed guidance on selecting measurement 
instruments for COS to aid developers in this process(39). 
 
(iii) We did not observe any relationship between the number of outcomes recommended by a COS 
and its rate of uptake.  However, in a survey about uptake of the PedIMMPACT COS for pediatric 
acute and chronic pain, some authors of systematic reviews felt that the six domains in the COS was 
too many(40).  It is possible, however, that it is the perceived burden on patients to complete the 
measures that lead to reluctance to implement them, as noted by Mulla et al. in their study of 
uptake of the IMMPACT COS for chronic pain(21).  COS developers may consider restricting the 
outcomes that are deemed to be core to a certain number, but in doing so need to consider the risk 
of missing a critical measurement from the core set.  COS developers should bear in mind the 
burden on both patients and healthcare professionals when considering outcomes and their 
measurement instruments. 
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 Several studies compared use of the outcomes that the COS recommended before and after 
publication of the COS(17, 19, 29).  Only one of these studies, which assessed a COS for ankylosing 
spondylitis, noted some increase in uptake of the full COS after publication (0% RCTs before versus 
20% RCTs after).  The survey investigating uptake of the PedIMMPACT COS found a lack of 
awareness of the COS, with only a third of authors of trials and systematic reviews who completed 
the survey being aware of the COS(40).  Lack of awareness was cited as an issue by a report of a 
similar survey for the IMMPACT COS for chronic pain(41).  The surveys also found that responders 
indicated that a lack of information about COS, lack of resources and time needed to use the COS, 
and in the case of systematic reviewers, the failure of RCTs to measure the COS outcomes, would 
affect use of the COS.  Difficulty in implementing the outcomes due to them being complicated was 
also noted.  To investigate barriers and facilitators to COS uptake in more detail, a qualitative study 
is currently underway by the first author of this report, in which trialists are taking part in interviews. 
 
We identified studies of COS uptake from the citation reports of COS publications.  A limitation of 
our study is that it is possible that there are studies of uptake that did not cite the COS that they 
were assessing and these would not have been identified in our search, however we consider this to 
be unlikely.   
 
Various strategies have been put in place to raise awareness of COS and encourage uptake.  A set of 
minimum standards for COS development, COS-STAD(42), has been published to guide COS 
developers in producing high quality COS and to give trialists considering a COS a benchmark against 
which to assess its quality.  To improve accessibility to COS, the COMET Initiative’s database provides 
a freely accessible resource that collates all COS publications and allows researchers to identify 
potentially relevant COS for their study.  Further strategies to consider in raising awareness include 
encouraging professional bodies to advocate for and promote COS, for example through inclusion of 
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the topic in educational programmes for researchers.  A recent survey of developers of published 
COS, carried out by the COMET Initiative, indicated that future studies of uptake are planned. 
 
Overall, the studies that had assessed uptake of a COS in full found low levels of uptake.  However, 
the standout exceptions to this were studies assessing uptake of the World Health Organisation and 
International League of Associations for Rheumatology COS for rheumatoid arthritis (RA).  The four 
studies assessing this COS show consistently high levels of uptake from 60-70% of RCTs measuring 
the full COS in one study, to 82% of RCTs in another.  In their 2013 assessment of the RA COS, 
Kirkham et al. suggested that this may be attributed in part to the endorsement of the COS by the 
Food and Drug Administration in 1996 and European Medicines Agency in 1998, after which they 
observed an increase in uptake(28).  In Kirkham’s subsequent review in 2017, it is noted that over 
80% of trials assessed received commercial funding and so would have followed EMA/FDA guidance, 
including about the COS(31).  In their third update of this work in 2019 the authors found that 
industry funded trials were more likely to measure the COS(32).  This might suggest that 
endorsement by drug regulatory agencies improves the uptake of COS in RCTs, but, in contrast, a 
study, that not only found a lower rate of uptake (45%) for the Knee, Hip and Hand Osteoarthritis 
(OA) COS, also reported a decrease in its uptake over time, and noted some inconsistency in 
recommendations across regulators, which may have impacted on the uptake of the COS(33). 
 
Some trial funders recommend the use of COS to their applicants (http://www.comet-
initiative.org/COSEndorsement).  A study assessed the impact of the National Institute for Health 
Research Health Technology Assessment’s (NIHR HTA) recommendation about COS and found that 
38% of applicants who submitted a researcher-led bid for funding between January 2012 and 
December 2015 searched for a COS (43).  Whilst the study concluded that trial funders can have an 
impact on COS uptake, it recommended further steps to increase this.  Similar studies are ongoing 
for the Health Research Board (HRB) and Deutsche Forschungsgemeinschaft, German Research 
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Foundation (DFG).  There is a need for ongoing evaluations of such system-level recommendations 
to identify what works, what does not, and why.   
 
With increased awareness of the need for COS and greater endorsement by influential organisations, 
we expect there to be more studies assessing COS uptake in the future. This review will serve as a 
benchmark for comparing uptake going forward.    
 
5. Conclusions 
To date, few studies have assessed uptake of COS in RCTs and SRs and further work is needed to 
assess this across a wider range of health and COS areas and to understand the barriers and 
facilitators for uptake. 
 
Figure 1: Identification of studies 
Figure 2: COS uptake studies by disease category 
Figure 3: Uptake of full COS in RCTs and SRs 
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